OnKure Therapeutics Q4 Financial Results Analysis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 12 2026
0mins
Should l Buy OKUR?
Source: seekingalpha
- Financial Performance: OnKure Therapeutics reported a GAAP EPS of -$0.09 for Q4 2025, indicating ongoing challenges in profitability, although losses have decreased compared to previous quarters.
- Cash Position: As of December 31, 2025, the company had approximately $59.1 million in cash and cash equivalents, ensuring liquidity for future R&D and operational needs, which is crucial for sustaining growth.
- R&D Expense Reduction: Q4 2025 R&D expenses were $10.7 million, down from $14.4 million in Q4 2024, with a $3.6 million decrease primarily driven by reduced consulting, outsourced R&D, and clinical trial costs, reflecting the company's focus on cost management.
- Administrative Cost Decline: General and Administrative expenses for Q4 2025 were $3.4 million, a decrease from $4.3 million in Q4 2024, mainly due to lower personnel-related costs and consulting fees, indicating improvements in operational efficiency.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OKUR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OKUR
Wall Street analysts forecast OKUR stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.590
Low
17.00
Averages
25.50
High
34.00
Current: 4.590
Low
17.00
Averages
25.50
High
34.00
About OKUR
OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using a structure-based drug design platform, the Company is building a pipeline of tumor-agnostic candidates. It is developing OKI-219, a selective PI3KaH1047R inhibitor, as its lead program. It is engaged in targeting oncogenic PI3Ka and has multiple programs designed to enable targeting of this key oncogene. It is focused on delivering highly selective drug candidates that preserve wild-type PI3Ka while targeting the PI3Ka-mutated cancers, initially in advanced breast cancer. Its lead product candidate, OKI-219, is advancing in a phase I clinical trial. It also focuses on a development candidate targeting the most common PI3Ka mutations, such as H1047R, E545K, and E542K. Additionally, it is developing an allosteric inhibitor molecule.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ONKURE THERAPEUTICS INC: PLANS TO SUBMIT IND APPLICATIONS FOR ALL PROGRAMS IN FIRST HALF OF 2027
Overview of Onkure Therapeutics: Onkure Therapeutics is expected to file INDs (Investigational New Drug applications) for each of its programs by 2027.
Focus on Therapeutics: The company is concentrating on developing innovative therapeutic solutions in the healthcare sector.
See More
OnKure Therapeutics Secures $150M in Private Placement Financing
- Financing Amount: OnKure Therapeutics announced a private placement financing agreement to raise approximately $150 million from institutional and healthcare investors, indicating strong market confidence in its future prospects.
- Share Issuance Details: The company will sell 26.71 million Class A shares at $4.15 each and issue pre-funded warrants for 9.43 million shares at $4.1499 each, with warrants exercisable immediately at $0.0001 per share, enhancing investor participation.
- Use of Proceeds: The net proceeds from this financing will be directed towards advancing the development of next-generation PI3Kα inhibitor candidates for breast cancer and vascular anomalies, as well as for working capital and general corporate purposes, highlighting the company's commitment to R&D.
- Market Reaction: Following the financing announcement, OnKure Therapeutics' shares rose by 14.75%, reflecting positive investor sentiment regarding the company's growth potential.
See More
NASDAQ 100 Pre-Market Indicator Declines Significantly
- Market Indicator Decline: The NASDAQ 100 Pre-Market Indicator has dropped by 150.28 points to 23,436.71, indicating weakened market sentiment that could impact investor confidence and lead to further selling pressure.
- Active Stock Performance: ProShares UltraPro QQQ (TQQQ) fell by $0.74 to $40.49 with a trading volume of 9,484,281 shares, representing a 131.37% increase from its 52-week low, demonstrating strong investor interest in this ETF.
- ETF Trading Dynamics: Direxion Daily TSLA Bull 2X ETF (TSLL) decreased by $0.16 to $12.09, with 6,547,620 shares traded, reflecting a 92.21% increase from its 52-week low, indicating market expectations of volatility in Tesla's stock.
- Stock Recommendation Status: OnKure Therapeutics, Inc. (OKUR) declined by $0.44 to $4.15, with a trading volume of 3,653,160 shares, and Zacks reports its current mean recommendation is in the 'buy range', potentially attracting more investor attention.
See More
OnKure Therapeutics Q4 Financial Results Analysis
- Financial Performance: OnKure Therapeutics reported a GAAP EPS of -$0.09 for Q4 2025, indicating ongoing challenges in profitability, although losses have decreased compared to previous quarters.
- Cash Position: As of December 31, 2025, the company had approximately $59.1 million in cash and cash equivalents, ensuring liquidity for future R&D and operational needs, which is crucial for sustaining growth.
- R&D Expense Reduction: Q4 2025 R&D expenses were $10.7 million, down from $14.4 million in Q4 2024, with a $3.6 million decrease primarily driven by reduced consulting, outsourced R&D, and clinical trial costs, reflecting the company's focus on cost management.
- Administrative Cost Decline: General and Administrative expenses for Q4 2025 were $3.4 million, a decrease from $4.3 million in Q4 2024, mainly due to lower personnel-related costs and consulting fees, indicating improvements in operational efficiency.
See More
ONKURE THERAPEUTICS INC REPORTS Q4 2025 NET LOSS OF $13.5 MILLION, EQUIVALENT TO $0.99 PER SHARE
- Financial Performance: Onkure Therapeutics reported a net loss of $13.5 million for Q4 2025, equating to $0.99 per share.
- Company Overview: Onkure Therapeutics is involved in the development of therapeutic solutions, though specific details about their products or services are not provided in the summary.
See More
VTI ETF Update, October 9, 2025
VTI Stock Performance: The Vanguard Total Stock Market ETF (VTI) has increased by 1.59% over the past week and 14.80% year-to-date, with a Moderate Buy consensus from analysts and a price target suggesting a 10.88% upside.
Holdings Analysis: VTI's top five holdings with the highest upside potential include Cibus, FibroBiologics, and Biodesix, while those with the greatest downside risk include Wolfspeed and Opendoor Technologies.
See More
ONKURE THERAPEUTICS INC: PLANS TO SUBMIT IND APPLICATIONS FOR ALL PROGRAMS IN FIRST HALF OF 2027
Overview of Onkure Therapeutics: Onkure Therapeutics is expected to file INDs (Investigational New Drug applications) for each of its programs by 2027.
Focus on Therapeutics: The company is concentrating on developing innovative therapeutic solutions in the healthcare sector.
See More
OnKure Therapeutics Secures $150M in Private Placement Financing
- Financing Amount: OnKure Therapeutics announced a private placement financing agreement to raise approximately $150 million from institutional and healthcare investors, indicating strong market confidence in its future prospects.
- Share Issuance Details: The company will sell 26.71 million Class A shares at $4.15 each and issue pre-funded warrants for 9.43 million shares at $4.1499 each, with warrants exercisable immediately at $0.0001 per share, enhancing investor participation.
- Use of Proceeds: The net proceeds from this financing will be directed towards advancing the development of next-generation PI3Kα inhibitor candidates for breast cancer and vascular anomalies, as well as for working capital and general corporate purposes, highlighting the company's commitment to R&D.
- Market Reaction: Following the financing announcement, OnKure Therapeutics' shares rose by 14.75%, reflecting positive investor sentiment regarding the company's growth potential.
See More
NASDAQ 100 Pre-Market Indicator Declines Significantly
- Market Indicator Decline: The NASDAQ 100 Pre-Market Indicator has dropped by 150.28 points to 23,436.71, indicating weakened market sentiment that could impact investor confidence and lead to further selling pressure.
- Active Stock Performance: ProShares UltraPro QQQ (TQQQ) fell by $0.74 to $40.49 with a trading volume of 9,484,281 shares, representing a 131.37% increase from its 52-week low, demonstrating strong investor interest in this ETF.
- ETF Trading Dynamics: Direxion Daily TSLA Bull 2X ETF (TSLL) decreased by $0.16 to $12.09, with 6,547,620 shares traded, reflecting a 92.21% increase from its 52-week low, indicating market expectations of volatility in Tesla's stock.
- Stock Recommendation Status: OnKure Therapeutics, Inc. (OKUR) declined by $0.44 to $4.15, with a trading volume of 3,653,160 shares, and Zacks reports its current mean recommendation is in the 'buy range', potentially attracting more investor attention.
See More
OnKure Therapeutics Q4 Financial Results Analysis
- Financial Performance: OnKure Therapeutics reported a GAAP EPS of -$0.09 for Q4 2025, indicating ongoing challenges in profitability, although losses have decreased compared to previous quarters.
- Cash Position: As of December 31, 2025, the company had approximately $59.1 million in cash and cash equivalents, ensuring liquidity for future R&D and operational needs, which is crucial for sustaining growth.
- R&D Expense Reduction: Q4 2025 R&D expenses were $10.7 million, down from $14.4 million in Q4 2024, with a $3.6 million decrease primarily driven by reduced consulting, outsourced R&D, and clinical trial costs, reflecting the company's focus on cost management.
- Administrative Cost Decline: General and Administrative expenses for Q4 2025 were $3.4 million, a decrease from $4.3 million in Q4 2024, mainly due to lower personnel-related costs and consulting fees, indicating improvements in operational efficiency.
See More
ONKURE THERAPEUTICS INC REPORTS Q4 2025 NET LOSS OF $13.5 MILLION, EQUIVALENT TO $0.99 PER SHARE
- Financial Performance: Onkure Therapeutics reported a net loss of $13.5 million for Q4 2025, equating to $0.99 per share.
- Company Overview: Onkure Therapeutics is involved in the development of therapeutic solutions, though specific details about their products or services are not provided in the summary.
See More
VTI ETF Update, October 9, 2025
VTI Stock Performance: The Vanguard Total Stock Market ETF (VTI) has increased by 1.59% over the past week and 14.80% year-to-date, with a Moderate Buy consensus from analysts and a price target suggesting a 10.88% upside.
Holdings Analysis: VTI's top five holdings with the highest upside potential include Cibus, FibroBiologics, and Biodesix, while those with the greatest downside risk include Wolfspeed and Opendoor Technologies.
See More
